POET Technologies Announces Operational, Financial

New Post Public Reply Private Reply Replies (0) Message Board
sevenOdouble
POET Technologies Announces Operational, Financial Position, "Lab-to-Fab" Transition, and Milestone Updates
TORONTO, ONTARIO and STORRS, CONNECTICUT--(Marketwired - Jan. 8, 2015) - POET Technologies Inc. (TSX VENTURETK)(OTCQXOETF) (the "Company" - developer of the planar opto-electronic technology ("POET" platform for monolithic fabrication of integrated circuit devices containing both electronic and optical elements on a single semiconductor wafer - today announced key operational, financial position, "Lab-to-Fab" transition, and milestone updates.

Financial Position

"POET enters 2015 in excellent financial shape," noted Mr. Peter Copetti, Co-Chairman and interim CEO. "Although we spent on outsourcing and capital equipment through 2014, we start the new year with a cash balance of approximately $12.5 million, a 350% increase from a year earlier. This is our strongest cash position as a company and will allow us to take advantage of opportunities in the following year to maximize shareholder value." In December 2014, the Company also signed a new lease extension with the University of Connecticut ("UCONN" for a 1-year period which was pre-paid at a significant discount. The new lease includes a possible further two-year extension and provides us the flexibility to transition from Lab to Fab.

Mr. Copetti added: "2014 has been a great year for POET where our transition from "Lab-to-Fab" has begun with many industry Non-Disclosure Agreement ("NDA" discussions that have been initiated through the work of Mr. Ajit Manocha, our Co-Chairman. Some of our milestones have had to evolve during 2014 because of industry relationship considerations and priorities. These evolving changes have made the updated milestones more significant to the market place. We enter 2015 with financial stability, significant industry relationships, and milestones relevant to the industry collaborators. The Company believes that we are in an excellent position to monetize our process technology."

"Lab-to-Fab" Transition: 100-nm and 40-nm Scaling Program Update

POET recently reported a contractual effort with a "3rd party foundry" to accelerate the transition from "Lab-to-Fab" of the POET technology to a manufacturing status at the 6" wafer scale. Significant progress has been made towards transfer of critical manufacturing steps to the "3rd party foundry". This flow will both accelerate and improve quality of results for prototype fabrication and test supporting process flow and design enablement kit development. Efforts in the lab have been geared towards optimization of the self-aligned contacts for the HFET transistors, as well as on optimization of the vertical structure of the devices. Mr. Daniel DeSimone, Chief Technology Officer noted: "We have seen positive improvement in the key figures of merit we test for in our devices. We see further possible improvements and are continuing to work on device and process flow to achieve the highest possible performance."

In a parallel development at the UCONN lab, a new additional sputter tool was received and accepted. The tool is nearing completion of internal qualification. Deployment of the new tool will drastically reduce prototype fabrication cycle times as well as improve the quality and process control of key films used in the process flow. These will be critical not only to current development, but also necessary for transfer to eventual manufacturing stages.

Milestone Updates

PET Foundation Process Design Kit ("PDK" targeting 40-nm - Sentaurus modeling (a Synopsys tool) has been performed with new fabrication innovations to achieve controlled scaled device operation. These modeling predictions are guiding and confirming the device prototype development and testing. The PDK milestone has been moved to Q1 2015 so that the release incorporates the latest innovations currently being developed in the UCONN Lab and in parallel with the "3rd party foundry".

"3rd Party Foundry" 40/100-nm Transfer - This "Lab-to-Fab" effort requires bringing up critical layers manufacturing capability in our "3rd party foundry" which enables more complex test structures. Significant progress has been achieved towards the completion of this milestone. The Company is very close to completing qualification runs for the flow in which the critical layers are performed at our "3rd party foundry". This new flow will significantly accelerate completion and optimization of development on 100 and 40-nm foundation devices and associated proof of concept optical and electronic circuit structures.

CEO Search Update

POET recently announced that Mr. Ajit Manocha, Co-Chairman had been appointed to the Corporate Governance and Nominating Committee, subject to Board approval, with the mandate to identify and consider candidates for the permanent Chief Executive Officer role. Mr. Manocha noted: "Several high quality candidates are being considered. We hope in the near term to identify POET's permanent CEO who will continue the process technology development and help us close key industry partnership deals. We look forward to identifying the right successor."

In addition, over the next few months, the Company intends to add directors, key executives and operational staff focusing on increasing POET's presence in the United States.

POET Technologies Inc. (POET) Stock Research Links

POET Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractal Sees Explosive Q2 Gain: Revenue Hits $100M

Updated Category News Views 80

Fractal’s Revenue Moment: Climbing New Peaks Fractal Analytics just knocked it out of the park, folks. Imagine this—an AI company pulling in $100 million for the first quarter, getting a 20% jump in revenue year on year. That's right, these numbers aren't just fancy figures; they're staggering proof that Fractal's hitting its AI stride. The healthcare and life...

Continue Reading
Micropos Medical's Push in High-Precision Radiotherapy

Updated Category News Views 59

Micropos Medical's Bold Steps into Radiotherapy Let's put a spotlight on a niche that's crying for attention: Micropos Medical is making waves in how we treat prostate cancer. They're leveraging technology with their Raypilot System, and they're partnering with the big guns at Johns Hopkins Medicine. Think about it — five patients in the U.S. are already seeing how this...

Continue Reading
Metals Producers Rise Despite Futures Dip: Election Day Buzz

Updated Category News Views 40

Election Day Drama: Metals Market Jitters You'd think with all the election day hoopla, the metal futures would hold steady. But here we are, seeing gold, silver, and copper futures retracting like a scared turtle. Monday, they all roared upward. Tuesday morning, they're backpedaling. December gold futures took a hit, dropping 0.78% to land at $3,938.50 an ounce. Silver...

Continue Reading
Kaolin Market Surges to $8.89B by 2031: Key Trends

Updated Category News Views 42

Riding the Kaolin Wave: Industrial Market Expansion You can't miss the sound of kaolin clinking in as it rides the tide of industrial demand. Reports from MarketsandMarkets™ have kaolin's party rocking all the way to a hefty $8.89 billion by 2031, up from $6.19 billion in 2026. With a sensible 7.5% compound annual growth rate (CAGR), this clay’s is aiming for the...

Continue Reading
PASCO scientific Appoints David Lopez as New CEO

Updated Category News Views 75

New Leadership at PASCO scientific Here's the scoop: PASCO scientific is shaking things up at the top by welcoming David Lopez into the CEO chair as of October 5, 2026. Lopez comes packing over two decades of experience in education and organizational leadership. He's stepping into a legacy that's all about making science hands-on and exciting for students—not just in...

Continue Reading
Scage Future's Next Leap: Mining with Autonomy

Updated Category News Views 24

Scage Future Drives Change with NCMCC Partnership Ever hear a platoon of autonomous trucks gearing up, ready to redefine the mining sector? That's exactly what’s brewing between Scage Future and China Huaye Group Co., Ltd. (NCMCC) from the latest update right out of Nanjing. Breaking Down the Deal They've slapped their signature on a non-binding agreement as of...

Continue Reading
SecureSpace Expands into Dallas-Fort Worth Market

Updated Category News Views 54

A New Player in Dallas-Fort Worth SecureSpace Self Storage has stormed into the Dallas-Fort Worth area, ushering in a sizeable expansion with four brand-new locations. This move is big news for the self-storage operator, marking its very first foray into the Texan market and boosting its nationwide presence past that century mark – 101 stores and counting. Call it a...

Continue Reading
WeSalute's 'Heroes Meet Heroes' Unites Military, Athletes

Updated Category News Views 62

Every now and then, something stirs the soul in a way that neither Wall Street nor Main Street quite can. The 14th annual 'Heroes Meet Heroes' event by WeSalute is poised to do just that. Celebrating Service Through Shared Experiences WeSalute has been a cornerstone for veteran recognition for over two decades, fostering a sense of unity between military service members...

Continue Reading
Silvercorp Updates El Domo Budget Amid Challenges

Updated Category News Views 53

Budget Pains for Silvercorp's El Domo Project Folks, if you thought navigating the stock market was a minefield, try mining these days. Silvercorp Metals Inc. had to bump up its budget for the El Domo project in Ecuador—again. This time by $14.6 million. What's causing this fiscal heartache? Everything from rising diesel prices thanks to Ecuador playing games with...

Continue Reading
Bright Minds Faces Legal Scrutiny Over FDA Trial Hold

Updated Category News Views 85

Bright Minds Biosciences Under the Microscope Well, it looks like Bright Minds Biosciences has found itself in some hot water with investors. After the FDA put a partial hold on their Phase 2 trial for BMB-101, designed for epilepsy treatment, the stock took a nosedive. If you're holding a piece of NASDAQ:DRUG, or even if you cut your losses and ran, it's time to tune in....

Continue Reading

Top 5 Most Recently Viewed Articles

SEATOM Selected for NATO's Accelerator Programme Growth

Updated Category News Views 161

SEATOM's Selection for NATO's Accelerator Programme Today, SEATOM announced a significant milestone as it was chosen to participate in the NATO Defence Innovation Accelerator for the North Atlantic (DIANA) 2026 Challenge Programme. This prestigious selection underscores SEATOM's innovative approach to developing nuclear technology tailored for maritime and extreme...

Continue Reading
OpenAI's New Device Development Following $6.5 Billion Acquisition

Updated Category News Views 194

OpenAI Completes a Major Acquisition OpenAI has recently wrapped up a remarkable deal by acquiring Jony Ive's AI hardware startup, io Products, for a staggering $6.5 billion. This acquisition brings the design genius, renowned for his work at a major tech giant, into OpenAI's fold to help create a new generation of smart devices. Key Developments Post-Acquisition The...

Continue Reading
Opportunities for KinderCare Investors Amid Class Action News

Updated Category News Views 151

Opportunities for KinderCare Investors Robbins Geller Rudman & Dowd LLP has announced a significant opportunity for investors of KinderCare Learning Companies, Inc. (NYSE: KLC) who have experienced substantial losses. This is a pivotal moment for shareholders as they can now seek to lead a class action lawsuit against the company. Understanding the Class Action Lawsuit...

Continue Reading
Baltic Horizon Fund Sees Positive NAV Growth in May 2025

Updated Category News Views 128

Growth of Baltic Horizon Fund's NAV in May 2025 The Baltic Horizon Fund reported an increase in its net asset value (NAV) per unit, which rose to EUR 0.6757 at the close of May 2025. This figure represents a slight gain from the NAV of EUR 0.6740 recorded at the end of April 2025. The fund's overall net asset value reached EUR 97.0 million, up from EUR 96.8 million in the...

Continue Reading
Autolus Therapeutics Highlights CARLYSLE Trial Findings at ASH 2025

Updated Category News Views 239

Autolus Therapeutics Showcases CARLYSLE Trial Results Autolus Therapeutics plc (Nasdaq: AUTL), a biopharmaceutical leader in developing innovative T cell therapies, recently showcased promising preliminary data from the CARLYSLE trial, which focuses on severe refractory systemic lupus erythematosus (srSLE). The data were presented during a special session at a leading...

Continue Reading